BACKGROUND: Despite multiple available options, the treatment of cutaneous melanoma metastases is often unsuccessful. Based on the hypothesis that imiquimod and 5-fluorouracil have synergistic antitumor properties, we used this topical combination to treat several patients. AIM: Our objective was to investigate the treatment combination in a small cohort of patients with surgically non-resectable melanoma metastases. METHODS: The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night. RESULTS: 45 lesions were treated. A clinical response was seen in 44 lesions, with a complete response in 19 lesions and a partial response in 25. Stable disease was confirmed in the 1 remaining lesion. No patients developed new lesions during treatment. However, one patient had a recurrence 6 months after treatment discontinuation, followed by a partial response when rechallenged. CONCLUSIONS: The imiquimod and 5-fluorouracil combination is effective. That patients did not develop new, distant lesions suggests the achievement of locoregional control, probably by the induction of antitumor immune response.
BACKGROUND: Despite multiple available options, the treatment of cutaneous melanoma metastases is often unsuccessful. Based on the hypothesis that imiquimod and 5-fluorouracil have synergistic antitumor properties, we used this topical combination to treat several patients. AIM: Our objective was to investigate the treatment combination in a small cohort of patients with surgically non-resectable melanoma metastases. METHODS: The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night. RESULTS: 45 lesions were treated. A clinical response was seen in 44 lesions, with a complete response in 19 lesions and a partial response in 25. Stable disease was confirmed in the 1 remaining lesion. No patients developed new lesions during treatment. However, one patient had a recurrence 6 months after treatment discontinuation, followed by a partial response when rechallenged. CONCLUSIONS: The imiquimod and 5-fluorouracil combination is effective. That patients did not develop new, distant lesions suggests the achievement of locoregional control, probably by the induction of antitumor immune response.
Authors: Michael P Schön; B Gregor Wienrich; Claudia Drewniok; Anne B Bong; Jürgen Eberle; Christoph C Geilen; Harald Gollnick; Margarete Schön Journal: J Invest Dermatol Date: 2004-05 Impact factor: 8.551
Authors: Smitha Gowda; Donald K Tillman; James E Fitzpatrick; Anthony A Gaspari; Gary Goldenberg Journal: J Cutan Pathol Date: 2009-08 Impact factor: 1.587
Authors: Anne B Bong; Bernd Bonnekoh; Ingolf Franke; Michael P Schön; Jens Ulrich; Harald Gollnick Journal: Dermatology Date: 2002 Impact factor: 5.366
Authors: T L Wagner; C L Ahonen; A M Couture; S J Gibson; R L Miller; R M Smith; M J Reiter; J P Vasilakos; M A Tomai Journal: Cell Immunol Date: 1999-01-10 Impact factor: 4.868
Authors: Daniel E Spratt; Elizabeth A Gordon Spratt; Shenhong Wu; Antonio DeRosa; Nancy Y Lee; Mario E Lacouture; Christopher A Barker Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Mary-Kate Malecek; June K Robinson; Karl Bilimoria; Jennifer N Choi; Jaehyuk Choi; Pedram Gerami; Timothy Kruser; Timothy Kuzel; Mary Martini; Jonathan B Strauss; Jeffrey Wayne; Jeffrey Sosman; Sunandana Chandra Journal: Melanoma Manag Date: 2016-08-16
Authors: Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar Journal: J Cancer Res Clin Oncol Date: 2018-08-09 Impact factor: 4.553
Authors: Hansje-Eva Teulings; Esther P M Tjin; Karina J Willemsen; Stephanie van der Kleij; Sylvia Ter Meulen; E Helen Kemp; Gabrielle Krebbers; Carel J M van Noesel; Cornelis L M C Franken; Jan W Drijfhout; Cornelis J M Melief; Ludmila Nieuweboer-Krobotova; Omgo E Nieweg; Jos A van der Hage; J P Wietze van der Veen; Germaine N Relyveld; Rosalie M Luiten Journal: Oncoimmunology Date: 2018-01-15 Impact factor: 8.110
Authors: Tavis Read; Scott Webber; Janine Thomas; Michael Wagels; Helmut Schaider; H Peter Soyer; B Mark Smithers Journal: BMJ Open Date: 2017-10-06 Impact factor: 2.692